As you age, your body accumulates senescent cells -- damaged cells that stop dividing but refuse to die. Instead of being cleared by the immune system, they linger, secreting inflammatory molecules that damage surrounding tissue. The longevity community calls them "zombie cells," and they are one of the most actionable hallmarks of aging.
Senolytic drugs are compounds designed to selectively destroy these cells. The most studied combination is dasatinib (a cancer drug) plus quercetin (a plant flavonoid), and the early human data is promising enough to pay attention to.
Why Senescent Cells Matter
Cellular senescence is a normal biological process. When a cell accumulates too much DNA damage, viral infection, or oncogenic stress, it enters a state of permanent growth arrest. This prevents potentially cancerous cells from dividing -- a useful protective mechanism.
The problem is accumulation. Young immune systems efficiently clear senescent cells. As you age, the clearance rate drops while the production rate increases. The result is a growing burden of senescent cells that secrete a cocktail of inflammatory molecules known as the SASP (senescence-associated secretory phenotype).
SASP includes pro-inflammatory cytokines (IL-6, IL-8, TNF-alpha), matrix metalloproteinases, and growth factors that:
- Drive chronic low-grade inflammation ("inflammaging")
- Degrade surrounding tissue architecture
- Convert neighboring healthy cells into senescent cells (paracrine senescence)
- Impair stem cell function
- Promote fibrosis and tissue dysfunction
Senescent cells typically make up a small percentage of total cells in any tissue, but their inflammatory secretions have outsized effects. Removing even a modest fraction of senescent cells in animal models has produced dramatic improvements in tissue function and lifespan.
The Animal Evidence
The landmark study came from the Mayo Clinic in 2011, when Dr. Jan van Deursen's lab demonstrated that genetically clearing senescent cells in mice delayed age-related pathology. Subsequent studies showed that pharmacological clearance using the dasatinib + quercetin (D+Q) combination could:
- Extend healthspan and lifespan in naturally aged mice
- Improve cardiac function in aged mice
- Reduce frailty and improve physical function
- Enhance bone density and reduce osteoporosis markers
- Improve vascular function
The mouse data is compelling. Intermittent dosing -- not daily treatment -- was sufficient to produce lasting benefits, because senescent cells take weeks to months to reaccumulate after clearance.
Dasatinib + Quercetin: The Combination
Dasatinib is an FDA-approved tyrosine kinase inhibitor used in cancer treatment. It targets senescent cell survival pathways including dependence on BCL-2 family proteins, PI3K/AKT signaling, and other anti-apoptotic networks. It appears particularly effective against senescent adipocyte progenitors and vascular cells.
Quercetin is a plant flavonoid found in onions, apples, and green tea. It has mild senolytic activity on its own, primarily targeting senescent endothelial cells and bone marrow stem cells. As a supplement, it is widely available and inexpensive.
The combination works because different senescent cell types rely on different survival pathways. Dasatinib and quercetin target complementary pathways, providing broader senolytic coverage than either compound alone.
Human Trial Data
The First Human Senolytic Trial
A 2019 pilot study published in EBioMedicine administered D+Q to patients with idiopathic pulmonary fibrosis (IPF) -- a disease characterized by senescent cell accumulation in the lungs. The protocol was 3 days of treatment per week for 3 weeks.
Results showed improvements in 6-minute walk distance, walking speed, and chair-stand tests. The effects persisted for weeks after the brief treatment period, consistent with the hypothesis that senescent cell clearance has durable benefits.
Diabetic Kidney Disease Trial
A study in patients with diabetic kidney disease showed that a single 3-day course of D+Q reduced senescent cell markers and SASP inflammatory molecules in adipose tissue. This confirmed that D+Q reaches target tissues and achieves senolytic activity in humans.
The human data is still extremely early. These are small pilot studies in specific disease populations, not large RCTs in healthy adults. Dasatinib is a chemotherapy drug with a real side effect profile including fluid retention, fatigue, GI issues, and cytopenias. This is not a casual supplement stack.
The Self-Experimenter Protocol
Despite the limited evidence, a D+Q protocol has emerged in the longevity community:
- Dasatinib: 100 mg
- Quercetin: 1000-1250 mg
- Schedule: Both taken together for 2-3 consecutive days, repeated monthly or quarterly
- Fasting: Some protocols recommend taking quercetin with a fat source for absorption and dasatinib on an empty stomach
The intermittent dosing is based on the principle that senescent cells take time to reaccumulate. Unlike daily medications, senolytics are designed as "hit and run" treatments -- clear the cells, then stop.
Quercetin Without Dasatinib
For those unwilling to use a prescription cancer drug (a reasonable position), quercetin alone or combined with fisetin (another flavonoid with senolytic properties) is a common alternative. The senolytic potency is likely lower than D+Q, but the risk profile is substantially better.
Fisetin showed promising senolytic activity in animal models and is being studied in human trials. A typical protocol is 1500-2000 mg of fisetin for 2 consecutive days, monthly.
Pros
- +Strong mechanistic rationale targeting a fundamental hallmark of aging
- +Animal data shows lifespan and healthspan extension
- +Early human trials show tissue-level senolytic activity
- +Intermittent dosing reduces exposure and side effect burden
- +Quercetin and fisetin are available as supplements
Cons
- -No completed large-scale human longevity trials
- -Dasatinib is a chemotherapy drug with meaningful side effects
- -Optimal dosing, timing, and frequency are not established
- -Quercetin alone may have limited senolytic potency
- -Long-term effects of periodic senescent cell clearance are unknown
What to Watch For
The field is moving quickly. Key trials to follow:
- UNITY Biotechnology's UBX1325: A targeted senolytic for age-related macular degeneration
- Mayo Clinic trials: Multiple ongoing studies of D+Q in various conditions
- Fisetin trials: Testing fisetin as a plant-derived senolytic with a better safety profile
Within 5-10 years, we should have substantially more human data on senolytics -- enough to make informed decisions about healthy adult use.
Be the first to try Prova
We're building an app to track whether senolytic protocol tracking actually works. Join the waitlist.
Frequently Asked Questions
This article is for informational purposes only and does not constitute medical advice. Dasatinib is a prescription medication with significant side effects. Do not use prescription senolytics without the supervision of a licensed healthcare provider.